Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all researchers worldwide, based on H-index of 58Recent studies advanced science of...
-
Roadzen Posts First ‘Rule of 40’ Quarter in Two Years; FY2026 Net Loss Narrows 69% and Adjusted EBITDA Loss Improves 58%, with Seventh Straight Quarter of Adjusted EBITDA Gains Nearing Breakeven ...
-
LOS ANGELES, June 29, 2026 (GLOBE NEWSWIRE) -- XMax Inc. (NASDAQ: XMAX; “XMax” or the “Company”), an artificial intelligence infrastructure provider and a distributor of contemporary-styled...
-
PARIS, June 29, 2026 (GLOBE NEWSWIRE) -- Pasqal, a global leader in neutral-atom quantum computing, today announced the appointment of Stéphane Rougeot as Chief Financial Officer (CFO). Rougeot — a...
-
Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial ...
-
BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for...
-
EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...
-
BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- GuideAI Health Corp. ("GuideAI" or the "Company") (Cboe CA: GDAI) is pleased to report that the Company has received final approval to list its common...
-
Latin Metals reports surface samples up to 63.88 g/t gold and 175.34 g/t silver at La Flora, advancing a high-grade target toward initial drilling.
-
- Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial1,2,3, EMBRACE, for...